As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Zivo Bioscience. The largest reported stake is Mark E. Strome's, at 12.1%. One filing is on record since February 27, 2026 (Schedule 13D/A, February 27, 2026).
Sell to companies like Zivo Bioscience? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Mark E. Strome · Sole voting: 194,303 · Shared voting: 278,639 · Sole dispositive: 194,303 · Shared dispositive: 278,639 · SCHEDULE 13D/A, 2026-02-27
- · Reporting person: Strome Group, Inc. · Sole voting: 0 · Shared voting: 278,639 · Sole dispositive: 0 · Shared dispositive: 278,639 · SCHEDULE 13D/A, 2026-02-27
- · Reporting person: Strome Investment Management, LP · Sole voting: 0 · Shared voting: 278,639 · Sole dispositive: 0 · Shared dispositive: 278,639 · SCHEDULE 13D/A, 2026-02-27
- · Reporting person: Strome Mezzanine Fund, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-02-27
- · Reporting person: Strome Mezzanine Fund II, LP · Sole voting: 0 · Shared voting: 266,198 · Sole dispositive: 0 · Shared dispositive: 266,198 · SCHEDULE 13D/A, 2026-02-27
Zivo Bioscience has 1 Schedule 13D or 13G filing on record since 2026-02-27. 1 holder's latest filing reports 5% or more of common stock, par value $.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 12.1% | 472,942 | SCHEDULE 13D/A, 2026-02-27 | 2025-12-31 |
Holding shares or following this stake? See who's behind Zivo Bioscience and the warning signs.
Free to see. No signup.
Keep reading
More on Zivo Bioscience and the records around it.
Zivo Bioscience elsewhere on the record
- Leadership changes Mar 2026
Companies that share a holder
- Mark E. Strome also filed stake reports on 2 other companies: Cue Biopharma, Inc. (Oct 2026), HeartBeam, Inc. (Aug 2026)
Watch Zivo Bioscience
Get an email when Zivo Bioscience files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zivo Bioscience?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Zivo Bioscience: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zivo Bioscience covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Mark E. Strome | 194,303 | 278,639 | 194,303 | 278,639 | SCHEDULE 13D/A, 2026-02-27 |
| Strome Group, Inc. | 0 | 278,639 | 0 | 278,639 | SCHEDULE 13D/A, 2026-02-27 |
| Strome Investment Management, LP | 0 | 278,639 | 0 | 278,639 | SCHEDULE 13D/A, 2026-02-27 |
| Strome Mezzanine Fund, LP | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-02-27 |
| Strome Mezzanine Fund II, LP | 0 | 266,198 | 0 | 266,198 | SCHEDULE 13D/A, 2026-02-27 |
The latest filing identifies Zivo Bioscience by CUSIP 98978N101 and gives its principal executive office as 21 E. Long Lake Road, Suite 100, Bloomfield Hills, MI 48304 (SCHEDULE 13D/A, 2026-02-27).
Source of funds (Item 3)
As a result of the merger described in Item 4, SMFII, as the surviving entity, succeeded to the 75,939 shares of Common Stock held by SMF immediately prior to the merger, and did not pay any consideration in connection therewith.Mark E. Strome, SCHEDULE 13D/A, 2026-02-27
Purpose of Transaction (Item 4)
Mark E. Strome
On December 31, 2025, the Funds effected a merger, with SMF merging into SMFII and SMFII as the surviving entity, by filing a Certificate of Merger with the Delaware Secretary of State. As a result of the merger, 75,939 shares of Common Stock held by SMF immediately prior to the merger are now held by SMFII.Item 4 of the SCHEDULE 13D/A filed 2026-02-27
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-27 | Mark E. Strome | 12.1% | SCHEDULE 13D/A |
Also on the record for Zivo Bioscience
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| March 30, 2026 | Leadership change: William A. Sullivan departs, Chief Financial Officer, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Zivo Bioscience. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.